These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
550 related articles for article (PubMed ID: 27029430)
41. Hypertonic stress modulates eNOS function through O-GlcNAc modification at Thr-866. Li C; He A; Guo Y; Yang X; Luo M; Cheng Z; Huang L; Xia Y; Luo S Sci Rep; 2021 May; 11(1):11272. PubMed ID: 34050207 [TBL] [Abstract][Full Text] [Related]
42. O-GlcNAcylation disrupts STRA6-retinol signals in kidneys of diabetes. Chen CH; Lin KD; Ke LY; Liang CJ; Kuo WC; Lee MY; Lee YL; Hsiao PJ; Hsu CC; Shin SJ Biochim Biophys Acta Gen Subj; 2019 Jun; 1863(6):1059-1069. PubMed ID: 30905621 [TBL] [Abstract][Full Text] [Related]
43. O-GlcNAcylation involvement in high glucose-induced cardiac hypertrophy via ERK1/2 and cyclin D2. Ding F; Yu L; Wang M; Xu S; Xia Q; Fu G Amino Acids; 2013 Aug; 45(2):339-49. PubMed ID: 23665912 [TBL] [Abstract][Full Text] [Related]
44. O-GlcNAc modification affects the ATM-mediated DNA damage response. Miura Y; Sakurai Y; Endo T Biochim Biophys Acta; 2012 Oct; 1820(10):1678-85. PubMed ID: 22759405 [TBL] [Abstract][Full Text] [Related]
45. Interplay between Akt and p38 MAPK pathways in the regulation of renal tubular cell apoptosis associated with diabetic nephropathy. Rane MJ; Song Y; Jin S; Barati MT; Wu R; Kausar H; Tan Y; Wang Y; Zhou G; Klein JB; Li X; Cai L Am J Physiol Renal Physiol; 2010 Jan; 298(1):F49-61. PubMed ID: 19726550 [TBL] [Abstract][Full Text] [Related]
46. Removal of Abnormal Myofilament O-GlcNAcylation Restores Ca2+ Sensitivity in Diabetic Cardiac Muscle. Ramirez-Correa GA; Ma J; Slawson C; Zeidan Q; Lugo-Fagundo NS; Xu M; Shen X; Gao WD; Caceres V; Chakir K; DeVine L; Cole RN; Marchionni L; Paolocci N; Hart GW; Murphy AM Diabetes; 2015 Oct; 64(10):3573-87. PubMed ID: 26109417 [TBL] [Abstract][Full Text] [Related]
47. Yeast cells as an assay system for in vivo O-GlcNAc modification. Nakanishi H; Li F; Han B; Arai S; Gao XD Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt A):1159-1167. PubMed ID: 28263870 [TBL] [Abstract][Full Text] [Related]
48. Modulation of O-GlcNAcylation Regulates Autophagy in Cortical Astrocytes. Rahman MA; Hwang H; Cho Y; Rhim H Oxid Med Cell Longev; 2019; 2019():6279313. PubMed ID: 31827688 [TBL] [Abstract][Full Text] [Related]
49. Attenuation of diabetic nephropathy by dietary fenugreek (Trigonella foenum-graecum) seeds and onion (Allium cepa) via suppression of glucose transporters and renin-angiotensin system. Pradeep SR; Barman S; Srinivasan K Nutrition; 2019; 67-68():110543. PubMed ID: 31408826 [TBL] [Abstract][Full Text] [Related]
50. Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells. Liu G; Shea CM; Jones JE; Price GM; Warren W; Lonie E; Yan S; Currie MG; Profy AT; Masferrer JL; Zimmer DP Am J Physiol Renal Physiol; 2020 Oct; 319(4):F697-F711. PubMed ID: 32865013 [TBL] [Abstract][Full Text] [Related]
51. Overexpression of O-GlcNAc-transferase associates with aggressiveness of mass-forming cholangiocarcinoma. Phoomak C; Silsirivanit A; Wongkham C; Sripa B; Puapairoj A; Wongkham S Asian Pac J Cancer Prev; 2012; 13 Suppl():101-5. PubMed ID: 23480751 [TBL] [Abstract][Full Text] [Related]
52. Inhibition of renin angiotensin system decreases renal protein oxidative damage in diabetic rats. Portero-Otín M; Pamplona R; Boada J; Jové M; Gonzalo H; Buleon M; Linz W; Schäfer S; Tack I; Girolami JP Biochem Biophys Res Commun; 2008 Apr; 368(3):528-35. PubMed ID: 18243127 [TBL] [Abstract][Full Text] [Related]
54. O-GlcNAcylation affects β-catenin and E-cadherin expression, cell motility and tumorigenicity of colorectal cancer. Harosh-Davidovich SB; Khalaila I Exp Cell Res; 2018 Mar; 364(1):42-49. PubMed ID: 29391154 [TBL] [Abstract][Full Text] [Related]
55. New insights: A role for O-GlcNAcylation in diabetic complications. Peterson SB; Hart GW Crit Rev Biochem Mol Biol; 2016; 51(3):150-61. PubMed ID: 26806492 [TBL] [Abstract][Full Text] [Related]
56. Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Satoh M; Fujimoto S; Arakawa S; Yada T; Namikoshi T; Haruna Y; Horike H; Sasaki T; Kashihara N Nephrol Dial Transplant; 2008 Dec; 23(12):3806-13. PubMed ID: 18596126 [TBL] [Abstract][Full Text] [Related]
57. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Zhang Z; Zhang Y; Ning G; Deb DK; Kong J; Li YC Proc Natl Acad Sci U S A; 2008 Oct; 105(41):15896-901. PubMed ID: 18838678 [TBL] [Abstract][Full Text] [Related]
58. Regulation of O-GlcNAcylation on endothelial nitric oxide synthase by glucose deprivation and identification of its O-GlcNAcylation sites. He A; Hu S; Pi Q; Guo Y; Long Y; Luo S; Xia Y Sci Rep; 2020 Nov; 10(1):19364. PubMed ID: 33168911 [TBL] [Abstract][Full Text] [Related]
59. Losartan, an angiotensin II type 1 receptor blocker, ameliorates cerebral ischemia-reperfusion injury via PI3K/Akt-mediated eNOS phosphorylation. Liu H; Liu X; Wei X; Chen L; Xiang Y; Yi F; Zhang X Brain Res Bull; 2012 Oct; 89(1-2):65-70. PubMed ID: 22766267 [TBL] [Abstract][Full Text] [Related]
60. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Onozato ML; Tojo A; Goto A; Fujita T; Wilcox CS Kidney Int; 2002 Jan; 61(1):186-94. PubMed ID: 11786100 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]